Cellular pharmacology of 3'-azido-3'-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells

JP Sommadossi, R Carlisle and Z Zhou

Department of Pharmacology, University of Alabama, Birmingham 35294.

We previously demonstrated that 3'-azido-3'-deoxythymidine (AZT) inhibits growth proliferation of human bone marrow progenitor cells in vitro [Antimicrob. Agents Chemother. 31:452-454 (1987)]. The present study evaluates the effect of toxic concentrations of AZT on possible sites of toxicity in human bone marrow cells. Exposure of cells over a 6-hr period to AZT concentrations between 0.5 and 50 microM resulted in a decreased incorporation of tritiated deoxyguanosine into DNA. Unchanged AZT and its phosphorylated metabolites accumulated within cells after exposure to 10 microM [3H]AZT. 3'-Azido-3'-deoxythymidine- 5'-monophosphate was the predominant metabolite, reaching a concentration of 49.2 +/- 14.1 pmol/10(6) cells after 48 hr, and a continuous increase was observed in all phosphorylated derivative levels between 2 and 48 hr of incubation. Using a highly sensitive and specific DNA polymerase assay, endogenous deoxyribonucleotide pool size(s) were analyzed for 48 hr after incubation of cells with a pharmacologically relevant concentration of 10 microM AZT. After a 6-hr exposure, 2'-deoxycytidine-5'-triphosphate and 2'-deoxythymidine-5'- triphosphate pools represented approximately 86 and 70% of the control values; levels returned to normal after 24 hr and remained subsequently unchanged. Nucleic acids of human bone marrow cells exposed for 24 hr to 10 microM [3H]AZT were purified and analyzed by cesium sulfate density gradient. No radioactivity was detected in the RNA region, whereas a significant amount was associated with the DNA region. Hydrolysis of radiolabeled DNA and subsequent analysis by high performance liquid chromatography demonstrated specific incorporation of AZT into DNA. In additional studies, the amount of AZT incorporated into DNA was correlated with the initial extracellular AZT concentration. In particular, a significant relationship (p less than 0.0001) between the level of AZT incorporated into DNA and the inhibition of clonal growth was observed at concentrations of AZT between 1 and 25 microM (IC50 and IC85 for human bone marrow cells). In summary, these studies demonstrate that AZT is incorporated into DNA of human bone marrow cells and suggest that incorporation of AZT into DNA may be one mechanism responsible for AZT-induced bone marrow toxicity. In contrast, imbalance of deoxyribonucleotide pools by AZT appears unlikely to be associated with inhibition of DNA synthesis and toxicity in human bone marrow cells.

Volume 36, Issue 1, pp. 9-14, 07/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				L D Lewis, S Amin, C I Civin, and P S Lietman Ex vivo zidovudine (AZT) treatment of CD34+ bone marrow progenitors causes decreased steady state mitochondrial DNA (mtDNA) and increased lactate production Human and Experimental Toxicology, April 1, 2004; 23(4): 173 - 185. [Abstract] [PDF]

				J.-Y. Liou, P. Krishnan, C.-C. Hsieh, G. E. Dutschman, and Y.-c. Cheng Assessment of the Effect of Phosphorylated Metabolites of Anti-Human Immunodeficiency Virus and Anti-Hepatitis B Virus Pyrimidine Analogs on the Behavior of Human Deoxycytidylate Deaminase Mol. Pharmacol., January 1, 2003; 63(1): 105 - 110. [Abstract] [Full Text] [PDF]

				O. A. Olivero, M. K. Reddy, S. M. Pietras, and M. C. Poirier Plasma Drug Levels Compared with DNA Incorporation of 3'-azido-3'-Deoxythymidine (AZT) in Adult Cynomolgus (Macaca fascicularis) Monkeys Experimental Biology and Medicine, May 1, 2001; 226(5): 446 - 449. [Abstract] [Full Text]

				M. L. Bryant, E. G. Bridges, L. Placidi, A. Faraj, A.-G. Loi, C. Pierra, D. Dukhan, G. Gosselin, J.-L. Imbach, B. Hernandez, et al. Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection Antimicrob. Agents Chemother., January 1, 2001; 45(1): 229 - 235. [Abstract] [Full Text]

				Q. Meng, D. M. Walker, O. A. Olivero, X. Shi, B. B. Antiochos, M. C. Poirier, and V. E. Walker Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells PNAS, October 26, 2000; (2000) 220203197. [Abstract] [Full Text]

				Q. Meng, A. J. Grosovsky, X. Shi, and V. E. Walker Mutagenicity and loss of heterozygosity at the APRT locus in human lymphoblastoid cells exposed to 3'-azido-3'-deoxythymidine Mutagenesis, September 1, 2000; 15(5): 405 - 410. [Abstract] [Full Text] [PDF]

				Q. Meng, T. Su, O. A. Olivero, M. C. Poirier, X. Shi, X. Ding, and V. E. Walker Relationships between DNA Incorporation, Mutant Frequency, and Loss of Heterozygosity at the TK Locus in Human Lymphoblastoid Cells Exposed to 3'-Azido-3'-deoxythymidine Toxicol. Sci., April 1, 2000; 54(2): 322 - 329. [Abstract] [Full Text] [PDF]

				X.-R. Pan-Zhou, L. Cui, X.-J. Zhou, J.-P. Sommadossi, and V. M. Darley-Usmar Differential Effects of Antiretroviral Nucleoside Analogs on Mitochondrial Function in HepG2 Cells Antimicrob. Agents Chemother., March 1, 2000; 44(3): 496 - 503. [Abstract] [Full Text]

				J.-P. Yan, D. D. Ilsley, C. Frohlick, R. Steet, E. T. Hall, R. D. Kuchta, and P. Melançon 3`-Azidothymidine (Zidovudine) Inhibits Glycosylation and Dramatically Alters Glycosphingolipid Synthesis in Whole Cells at Clinically Relevant Concentrations J. Biol. Chem., September 29, 1995; 270(39): 22836 - 22841. [Abstract] [Full Text] [PDF]

				H Pelletier, M. Sawaya, A Kumar, S. Wilson, and J Kraut Structures of ternary complexes of rat DNA polymerase beta, a DNA template-primer, and ddCTP Science, June 24, 1994; 264(5167): 1891 - 1903. [Abstract] [PDF]

				Q. Meng, D. M. Walker, O. A. Olivero, X. Shi, B. B. Antiochos, M. C. Poirier, and V. E. Walker Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells PNAS, November 7, 2000; 97(23): 12667 - 12671. [Abstract] [Full Text] [PDF]